184 related articles for article (PubMed ID: 36509836)
21. Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.
Smith RL; Molden E; Bernard JP
Br J Clin Pharmacol; 2023 Jul; 89(7):2246-2253. PubMed ID: 36851891
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.
Abdullah-Koolmees H; van Keulen AM; Nijenhuis M; Deneer VHM
Front Pharmacol; 2020; 11():595219. PubMed ID: 33568995
[TBL] [Abstract][Full Text] [Related]
23. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
24. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST; Steeves TD; Pringsheim T
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
[TBL] [Abstract][Full Text] [Related]
26. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
[TBL] [Abstract][Full Text] [Related]
27. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
[TBL] [Abstract][Full Text] [Related]
28. Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
de Leon J
J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):532-4. PubMed ID: 26088654
[No Abstract] [Full Text] [Related]
29. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
Notsu Y; Shimizu M; Sasaki T; Nakano A; Ota M; Yoshida S; Yamazaki H
Drug Metab Pharmacokinet; 2020 Apr; 35(2):191-200. PubMed ID: 32184039
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Yu G; Li GF; Markowitz JS
J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
[TBL] [Abstract][Full Text] [Related]
31. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
[TBL] [Abstract][Full Text] [Related]
32. Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.
Byeon JY; Kim YH; Na HS; Jang JH; Kim SH; Lee YJ; Bae JW; Kim IS; Jang CG; Chung MW; Lee SY
Arch Pharm Res; 2015 Nov; 38(11):2083-91. PubMed ID: 26254792
[TBL] [Abstract][Full Text] [Related]
33. Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.
Fu D; Guo HL; Hu YH; Fang WR; Liu QQ; Xu J; Wu DD; Chen F
Eur J Clin Pharmacol; 2023 Mar; 79(3):349-370. PubMed ID: 36645468
[TBL] [Abstract][Full Text] [Related]
34. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
Fu D; Guo HL; Hu YH; Chen F
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
[TBL] [Abstract][Full Text] [Related]
35. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
36. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
37. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data.
Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M
Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851
[TBL] [Abstract][Full Text] [Related]
38. Effect of 24 Cytochrome P450 2D6 Variants Found in the Chinese Population on Atomoxetine Metabolism in vitro.
Liang B; Zhan Y; Wang Y; Gu E; Dai D; Cai J; Hu G
Pharmacology; 2016; 97(1-2):78-83. PubMed ID: 26666748
[TBL] [Abstract][Full Text] [Related]
39. Potential interactions of methylphenidate and atomoxetine with dextromethorphan.
Ciccone PE; Ramabadran K; Jessen LM
J Am Pharm Assoc (2003); 2006; 46(4):472-8. PubMed ID: 16913391
[TBL] [Abstract][Full Text] [Related]
40. Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.
Caspar SM; Schneider T; Meienberg J; Matyas G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
